McKesson stock has delivered a 337.6% total return over the past five years, yet the latest valuation checks suggest the shares still lean cheap rather than stretched. The stock trades at about 19.8 times earnings, a clear discount to the Healthcare sector average of roughly 24.9 times and a peer group average near 24.1 times. Simply Wall St's fair price-to-earnings model implies a multiple of 29.6 times, materially above the current level, indicating the market has not fully closed the valuation gap. On broader checks, McKesson screens as undervalued in five of six valuation tests, pointing to a stock that still looks attractively priced against several fundamental yardsticks. The discount appears tied to concerns about thin distribution margins and execution risk, leaving the key question of whether those risks justify the gap or if the stock merits a multiple closer to its healthcare peers.
McKesson CorporationArticle states McKesson trades at a discount to peers and screens undervalued on multiple valuation tests, implying upside potential.